Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CMSC 2022 | Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases

Bruce Cree, MD, PhD, MAS, University of California San Francisco, San Francisco, CA, comments on the findings of a post-hoc analysis of the N-MOmentum trial (NCT02200770) in an interview recorded at the Consortium of Multiple Sclerosis Centers (CMSC) congress 2022 in Maryland. The N-MOmentum trial assessed the effectiveness of inebilizumab, an antibody approved by the FDA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are AQP4-IgG seropositive. The post-hoc analysis questioned whether inebilizumab was effective in patients with a single NMOSD attack as well as patients that have experienced more attacks. Prof. Cree explains that this is important to consider in order to widen treatment options for newly diagnosed individuals, who could potentially be good candidates for this disease modifying therapy. Alternatively, individuals with a history of many attacks are likely to have been exposed to other disease modifying therapies previously, illustrating the need for testing the effectiveness of inebilizumab in these situations as well. The post-hoc analysis observed that, regardless of number of attacks, inebilizumab consistently provided therapeutic benefits, meaning inebilizumab can be used in newly diagnosed NMOSD patients and more established NMOSD cases.


Bruce Cree has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics and Therini and received research support from Genentech.